Germ-line and somatic \textit{EPHA2} coding variants in lens aging and cataract

Thomas M. Bennett\textsuperscript{1}, Oussama M’Hamdi\textsuperscript{2}, J. Fielding Hejtmancik\textsuperscript{2}, Alan Shiels\textsuperscript{1}\textsuperscript{*}

\textsuperscript{1} Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States of America, \textsuperscript{2} Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States of America

\textsuperscript{*} shiels@vision.wustl.edu

Abstract

Rare germ-line mutations in the coding regions of the human \textit{EPHA2} gene (\textit{EPHA2}) have been associated with inherited forms of pediatric cataract, whereas, frequent, non-coding, single nucleotide variants (SNVs) have been associated with age-related cataract. Here we sought to determine if germ-line \textit{EPHA2} coding SNVs were associated with age-related cataract in a case-control DNA panel (> 50 years) and if somatic \textit{EPHA2} coding SNVs were associated with lens aging and/or cataract in a post-mortem lens DNA panel (> 48 years). Micro-fluidic PCR amplification followed by targeted amplicon (exon) next-generation (deep) sequencing of \textit{EPHA2} (17-exons) afforded high read-depth coverage (1000x) for > 82% of reads in the cataract case-control panel (161 cases, 64 controls) and > 70% of reads in the post-mortem lens panel (35 clear lens pairs, 22 cataract lens pairs). Novel and reference (known) missense SNVs in \textit{EPHA2} that were predicted in silico to be functionally damaging were found in both cases and controls from the age-related cataract panel at variant allele frequencies (VAFs) consistent with germ-line transmission (VAF > 20%). Similarly, both novel and reference missense SNVs in \textit{EPHA2} were found in the post-mortem lens panel at VAFs consistent with a somatic origin (VAF > 3%). The majority of SNVs found in the cataract case-control panel and post-mortem lens panel were transitions and many occurred at di-pyrimidine sites that are susceptible to ultraviolet (UV) radiation induced mutation. These data suggest that novel germ-line (blood) and somatic (lens) coding SNVs in \textit{EPHA2} that are predicted to be functionally deleterious occur in adults over 50 years of age. However, both types of \textit{EPHA2} coding variants were present at comparable levels in individuals with or without age-related cataract making simple genotype-phenotype correlations inconclusive.

Introduction

Cataract(s) is a clinically heterogeneous disorder that causes clouding or opacification of the crystalline lens and, thereby, impairs refraction and focusing of light onto the photosensitive retina of the eye. Typically, cataract is acquired with aging (> 50 years) and, despite surgical treatment, age-related cataract remains a leading cause of adult visual impairment (17%-33%).
and blindness (33%-51%) worldwide [1–3]. Besides aging, epidemiological studies have identified multiple environmental or lifestyle risk factors for age-related cataract including, solar UV-radiation exposure, tobacco smoking, and diabetes [4–6]. In addition, genetic factors are believed to account for 35–58% of the risk for age-related cataract [7,8]. Beyond age-related cataract, congenital, infantile and childhood forms of cataract that occur with relatively low prevalence (1–15 cases/10,000) account for 1.4%-34% of pediatric visual impairment globally [9–12]. Etiological studies of pediatric cataract reveal that genetic causes account for 10%-39% of cases; however, this may represent an underestimate since 50%-60% of cases are deemed idiopathic [10,11,13]. So far, genetic studies have identified at least 30 genes underlying inherited forms of pediatric cataract and several of these genes have also been implicated in the much more common forms of age-related cataract [14,15].

EPH-receptor A2 (EPHA2) is a member of the erythropoietin-producing hepatocellular-carcioma (EPH) sub-family of receptor tyrosine kinases (RTKs) that play critical signaling roles in embryonic development, adult tissue homeostasis, and cancer development and progression [16–20]. Structurally, EPHA2 is a type-1 (single-pass) transmembrane glycoprotein (~130kDa) with multiple functional domains including an extracellular (N-terminal) ligand binding domain (LBD) for eph-receptor interacting (ephrin) ligands and cytoplasmic (C-terminal) domains including a tyrosine kinase (TK) signaling domain and a sterile-α-motif (SAM) domain implicated in receptor clustering and protein-protein interactions [21,22]. First identified as epithelial cell kinase (eck) [23], EPHA2 is widely expressed in epithelial tissues and is surprisingly abundant in the plasma-membrane proteome of the ocular lens in both humans and mice [24,25], where it is believed to function in lens cell migration and organization [26–29].

Genetic studies have identified germ-line mutations in the human EPHA2 gene (EPHA2) on chromosome 1p that underlie inherited forms of pediatric cataract exhibiting both autosomal dominant and recessive modes of inheritance [30–43]. EPHA2-related cataract may present at birth (congenital), during infancy or during childhood and displays variable clinical morphology including posterior polar opacities, nuclear opacities, cortical opacities and total lens opacities (https://sites.wustl.edu/catmap). Currently, the EPHA2 mutation spectrum includes 14 missense mutations predicted to result in amino-acid substitutions, one nonsense mutation, and five frame-shift mutations predicted to result in either C-terminally truncated or extended proteins. Most of these mutations (13/20) occur in cytoplasmic domains of EPHA2 with four mutations clustered within the SAM domain and two in the TK domain. Ectopic overexpression studies in cultured cells suggest that mutations in the SAM domain destabilize the receptor and/or impair targeting to the plasma-membrane [44,45].

Beyond rare mutations, single nucleotide polymorphisms/variants (SNPs/SNVs) across the EPHA2 region have been variably associated with the much more prevalent forms of age-related cataract including cortical cataract, posterior sub-capsular cataract (PSC) and mixed forms of lens opacities in Caucasian/European, Asian/Indian and Chinese populations [26,30,46–50]. While most of the associated SNVs were located in non-coding or untranslated regions (UTRs), at least one rare, non-synonymous (missense), coding SNV (rs116506614) predicted to result in an amino-acid substitution (p.R721Q) has been associated with age-related cataract [26]. Further, in silico prediction analysis suggests that several other missense SNVs in EPHA2 (e.g. rs229180, p.E825K) may have deleterious effects on receptor function [51] and expression of several EPHA2 coding SNVs (rs1058371—p.I96F, p.E825K) in cultured lens epithelial cells has been associated with receptor destabilization and increased susceptibility to oxidative stress [52]. These observations suggest that rare coding SNVs in EPHA2 may increase susceptibility to age-related forms of cataract. Here we sought to determine whether rare coding SNVs...
in *EPHA2*, of either germ-line or somatic origin, were associated with lens aging and/or age-related cataract.

**Materials and methods**

**Ethics statement**

Ethical approval for this study was obtained from the University of Parma, the National Eye Institute, and Washington University (IRB ID #: 201111056 and 00–0320), and written informed consent was provided in accordance with the tenets of the Declaration of Helsinki.

**Cataract case-control DNA panel**

Genomic DNA was extracted using standard methods from blood samples donated by a case-control cohort of unrelated individuals age ≥50 years form Northern Italy that were ascertained from the Clinical Trial of Nutritional Supplements (CTNS) and Age-Related Cataract Study [53,54]. Cataract status (nuclear, cortical, posterior sub-capsular, clear lens) was evaluated by grading slit-lamp and retro-illumination lens photographs according to a modification of the Age-Related Eye Disease Study (AREDS) cataract grading system as described [55].

**Lens DNA panel**

Post-mortem human donor lenses (≥48 years of age, with or without cataract) were obtained (on dry-ice) from the National Disease Research Interchange (http://ndriresource.org/). Lens genomic DNA was extracted using the DNeasy Kit (Qiagen, Valencia, CA) essentially according to the manufacturer’s protocol with the following modifications to mitigate the high protein-to-DNA content of the lens. Each lens was homogenized (2 min—setting 8, Bullet Blender 24, Next Advance, Averill park, NY) in buffer ATL (360 ul) then digested (16 hr, 56˚C) with proteinase K (40 ul 15 mg/ml). Samples were then diluted with buffer ATL (360ul) and re-digested (2 hr, 56˚C) with proteinase K (40 ul) followed by centrifugation (5 min, 10,000 x g) to remove excess protein before processing through spin-columns according to the manufacturer’s instructions. DNA was eluted from the spin-columns in buffer AE (200 ul) and quantified (OD$_{260}$) using a spectrophotometer (ND-2000, NanoDrop, Wilmington, DE). If necessary, samples were concentrated by air-drying in a laminar-flow hood and re-suspended in ultrapure water to give a minimum concentration of 50 ng/μl required for amplicon sequencing.

**Targeted-amplicon deep-sequencing and variant calling**

Targeted-amplicon deep-sequencing was performed using the Access Array Integrated Fluidic Circuit (IFC) System with custom designed and validated gene-specific adaptor-primers (Fluidigm, San Francisco, CA). Each IFC enables nanoliter-volume high-throughput PCR to generate amplicons (≤200 bp) across 48 samples in a single run for subsequent next-generation (deep)-sequencing (NGS). Briefly, DNA samples (50 ng) and primers were mixed ‘on-chip’ (48.48 Access Array IFC/pre-PCR IFC Controller AX), and PCR amplified (FC1 Cycler). Amplicons for each sample were pooled on-chip (post-PCR IFC Controller AX) then indexed with sample barcodes and NGS adaptors (Access Array Barcode kit) to produce 48 sequencer-ready libraries. Sequencing-by-synthesis was performed on the MiSeq platform (Illumina, San Diego, CA). Paired-end reads were aligned to the human reference genome (hg19) with Novoalign (www.novocraft.com) and processed using the Sequence Alignment/Map (SAM) tools software package and Picard programs (http://samtools.sourceforge.net/). Variants were called using the FreeBayes program (https://arxiv.org/abs/1207.3907) for
germ-line variants and the VarScan 2 program for somatic variants [56,57] (http://varscan.sourceforge.net). Finally, selected SNVs were confirmed in both directions by manual inspection using the Integrative Genomics Viewer (IGV) browser [58] (http://software.broadinstitute.org/software/igv/).

Statistical analysis
Genetic association analysis and logistic regression analysis of selected SNVs found in the cataract case-control panel was performed using the Golden Helix SNP and Variation Suite 7 (Golden Helix, Bozeman, MT). Statistical comparison of somatic SNVs found in the post-mortem lens panel was performed using Fisher’s Exact Test by means of the online spreadsheet at http://www.langsrud.com/fisher.htm. A probability (p) value of < 0.05 after correction for multiple testing was considered significant.

Results
DNA panels
The cataract case-control panel comprised 225 leukocyte DNA samples from 161 patients with age-related cataract (age 50+) and 64 age-matched clear lens controls from the N. Italian population [53,54]. The cataract cases included 67 nuclear only, 43 cortical only, and two posterior sub-capsular cataract (PSC) only. In addition to ‘pure’ forms of cataract, there were multiple cases of mixed cataract including 21 nuclear + cortical, 14 nuclear + PSC, 10 cortical + PSC, and four nuclear + cortical + PSC. The mean age of cataract cases = 74.2 ± SD 6.54 years (range 50–85 years) and the mean age of clear lens controls = 75.19 ± SD 4.2 years (range 57–86), with no significant difference between cases and controls (p = 0.21). The sex distribution was 50% female and 50% male in the cases and 44% female and 56% male in the controls. There was no association between any cataract and sex in the case-control panel using chi-square test (p = 0.51).

Post-mortem donor lenses were briefly examined at the time of procurement for the presence or absence of obvious age-related cataract prior to cryopreservation. However, the donor information report did not identify age-related cataract sub-types (e.g. nuclear, cortical). Further, we cannot exclude the possibility that cataract in some of these donor lenses may have been associated with causes other than aging (e.g. uveitis). The post-mortem lens panel comprised 118 genomic DNA samples extracted from 74 clear lenses (37 pairs) and 44 cataract lenses (22 pairs) all obtained from Caucasian donors (age 48+ years). Two of the clear lens pairs failed amplicon sequencing and/or QC criteria leaving 114 lens samples (35 clear pairs, 22 cataract pairs) for variant analysis. The mean age of cataract lenses = 65.5 ± SD 6.67 (range 48–74 years) and the mean age of clear lenses = 64.06 ± SD 7.37 (range 48–78 years) with no significant difference between the two groups (p = 0.45). The sex distribution was 23% female and 77% male in the cataract lenses and 49% female and 51% male in the clear lenses. Despite the numerical sex difference in the cataract lenses there was no significant association between any cataract and sex in the post-mortem lens panel using chi-square test (p = 0.095).

Targeted-amplicon deep-sequencing of exonic variants
We performed targeted-amplicon deep-sequencing of the coding regions (exons) of the human EPHA2 gene to identify germ-line single nucleotide variants (SNVs) in the cataract case-control panel and somatic SNVs in the lens panel. EPHA2 (GenID: 1969) spans ~31.8 Kbp on the short (p) arm of chromosome 1 (cytogenetic band region 1p36.1) [59] with a physical location between nucleotides (nt) 16124337–16156104 (counted from the short-arm
telomere, ptel) on the complement strand [Annotation release 108, Genome Reference Consortium Human Build 38 patch release 7 (GRCh38.p7)] (http://www.ncbi.nlm.nih.gov/gene/1969). Currently, the gene reference sequence (NG_021396.1) comprises 17 coding exons generating two transcript variants, NM_004431.4 and NM_001329090.1, encoding protein isoforms of 976 amino acids (NP_004422.2) and 922 amino acids (NP_001316019), respectively. For comparison with EPHA2, we simultaneously performed amplicon sequencing of the gene coding for cellular tumor antigen p53 (TP53)—a tumor suppressor gene that is known to acquire somatic mutations in several cancers (e.g. cutaneous melanoma) (http://cancer.sanger.ac.uk/cosmic). TP53 (Gene ID: 7157) spans ~19.15 Kbp on chromosome 17p13.1 (7668402–7687550, complement) and the gene reference sequence (NG_017013.2) comprises 11 coding exons giving rise to 8 transcript variants and 12 protein isoforms (a-l) ranging from 182–393 amino-acids (http://www.ncbi.nlm.nih.gov/gene/7157).

Optimal custom design of PCR primer pairs (Fluidigm) to amplify exons for deep-sequencing resulted in 35 amplicons for EPHA2 and 15 amplicons for TP53. Across the cataract case-control panel the mean total number of reads was 418,214 with >99% on target of which >82% attained 1000x coverage (S1 Table). Similarly, across the lens panel the mean total number of reads was 456,286 with >99% on target of which >70% attained 1000x coverage (S1 Table). All amplicons were fully sequenced in both directions with the exception of amplicon 35 in EPHA2 (part of exon-1) likely due to its high G/C content.

Following sequencing, germ-line SNVs in the cataract case-control panel (blood leukocyte DNA) were called using the FreeBayes program. Variant allele frequencies (VAFs) were calculated as a percentage by dividing the number of individual variant reads by the total number of amplicon reads and those SNVs with VAFs ≥20% were designated germ-line. Somatic variants in the lens DNA panel were called using the VarScan 2 program that was originally designed to call low-frequency (>1%) somatic variants from deep-sequencing data derived from matched tumor (case) versus control tissue samples [56,57]. For our purposes, we compared left and right lenses from the same individual using the paired analysis or somatic mode. Rare variants present in both lenses were designated as germ-line, whereas, those present in only the left or the right lens (i.e. discordant SNVs) were designated as somatic. In order to reduce the risk of false positives we excluded somatic SNVs with VAFs below 3% and/or coverage depths below 600 reads as potential sequencing errors. For convenience, germ-line and somatic SNVs were divided into novel and reference categories to denote their absence or presence, respectively, in public genome databases including the Single Nucleotide Polymorphism database (dbSNP build 138), Exome Variant Server (EVS), Exome Aggregation Consortium (ExAC), 1000 Genomes project (1000G), and Catalogue of Somatic Mutations in Cancer (COSMIC). Both categories predominantly contained synonymous and non-synonymous (i.e. missense) SNVs with in silico predictions of damaging or deleterious effects at the protein level determined using appropriate algorithms (e.g. SIFT and PolyPhen-2). Binary versions (.bam files) of the Sequence Alignment/Map (.sam) files have been deposited with the NIH Short Read Archive (SRA Accession no. PRJNA384802).

Germ-line EPHA2 variants in the cataract case-control panel

Exon deep-sequencing of EPHA2 in the cataract case-control panel detected 10 novel SNVs (all transitions) and 20 reference SNVs (18 transitions) in the exon regions of EPHA2 at VAFs >20%—consistent with germ-line transmission (Table 1). Of the novel SNVs, two were synonymous and eight were non-synonymous—predicted to result in missense amino-acid substitutions. Two of the novel missense SNVs (p.I142T, p.W348R) occurred in controls and both were predicted in silico to be damaging. Of the remaining six missense SNVs found
Table 1. Germ-line EPHA2 coding SNVs found in the cataract case-control panel (VAF >20%).

| Exon Ref. Seq. no. | DNA Change | Protein Change | Amino-Acid Domain | PolyPhen-2 (prediction) | SIFT (prediction) | MAF—EVS Caucasian | MAF—1000G (CEU) | MAF—Cataract Case-Control Panel | Clear Lens Cataract | Cortical Cataract | Nuclear Cataract | PSC Mixed Cataract |
|-------------------|------------|----------------|-------------------|-------------------------|-------------------|-------------------|----------------|---------------------------------|------------------|----------------|----------------|-------------------|
| 2                 | rs147977279 | c.121C>G       | LBD               | 0.998 (D)               | 0.0000             | 0.0000            | 0.998 (D)       | 0.0000             | 0.0000             | 0.0000             | 0.0000             | 0.0000             |
| 3                 | rs6872816   | c.1648C>T      | LBD               | 0.959 (D)               | 0.0000             | 0.0022            | 0.959 (D)       | 0.0000             | 0.0000             | 0.0000             | 0.0000             | 0.0000             |
| 4                 | rs68733465  | c.1958C>T      | LBD               | 0.998 (D)               | 0.0000             | 0.0022            | 0.998 (D)       | 0.0000             | 0.0000             | 0.0000             | 0.0000             | 0.0000             |
| 5                 | rs68733465  | c.1958C>T      | LBD               | 0.998 (D)               | 0.0000             | 0.0022            | 0.998 (D)       | 0.0000             | 0.0000             | 0.0000             | 0.0000             | 0.0000             |
| 6                 | rs3475346   | c.2418G>A      | LBD               | 0.998 (D)               | 0.0000             | 0.0022            | 0.998 (D)       | 0.0000             | 0.0000             | 0.0000             | 0.0000             | 0.0000             |
| 7                 | rs147977279 | c.121C>G       | LBD               | 0.998 (D)               | 0.0000             | 0.0022            | 0.998 (D)       | 0.0000             | 0.0000             | 0.0000             | 0.0000             | 0.0000             |
| 8                 | rs6872816   | c.1648C>T      | LBD               | 0.959 (D)               | 0.0000             | 0.0022            | 0.959 (D)       | 0.0000             | 0.0000             | 0.0000             | 0.0000             | 0.0000             |
| 9                 | rs68733465  | c.1958C>T      | LBD               | 0.998 (D)               | 0.0000             | 0.0022            | 0.998 (D)       | 0.0000             | 0.0000             | 0.0000             | 0.0000             | 0.0000             |
| 10                | rs3475346   | c.2418G>A      | LBD               | 0.998 (D)               | 0.0000             | 0.0022            | 0.998 (D)       | 0.0000             | 0.0000             | 0.0000             | 0.0000             | 0.0000             |
| 11                | rs6872816   | c.1648C>T      | LBD               | 0.959 (D)               | 0.0000             | 0.0022            | 0.959 (D)       | 0.0000             | 0.0000             | 0.0000             | 0.0000             | 0.0000             |
| 12                | rs68733465  | c.1958C>T      | LBD               | 0.998 (D)               | 0.0000             | 0.0022            | 0.998 (D)       | 0.0000             | 0.0000             | 0.0000             | 0.0000             | 0.0000             |
| 13                | rs3475346   | c.2418G>A      | LBD               | 0.998 (D)               | 0.0000             | 0.0022            | 0.998 (D)       | 0.0000             | 0.0000             | 0.0000             | 0.0000             | 0.0000             |
| 14                | rs147977279 | c.121C>G       | LBD               | 0.998 (D)               | 0.0000             | 0.0022            | 0.998 (D)       | 0.0000             | 0.0000             | 0.0000             | 0.0000             | 0.0000             |
| 15                | rs6872816   | c.1648C>T      | LBD               | 0.959 (D)               | 0.0000             | 0.0022            | 0.959 (D)       | 0.0000             | 0.0000             | 0.0000             | 0.0000             | 0.0000             |
| 16                | rs68733465  | c.1958C>T      | LBD               | 0.998 (D)               | 0.0000             | 0.0022            | 0.998 (D)       | 0.0000             | 0.0000             | 0.0000             | 0.0000             | 0.0000             |
| 17                | rs3475346   | c.2418G>A      | LBD               | 0.998 (D)               | 0.0000             | 0.0022            | 0.998 (D)       | 0.0000             | 0.0000             | 0.0000             | 0.0000             | 0.0000             |

(B)—benign, (P)—probably damaging, (D)—damaging, (T)—tolerated.
in cases, two were predicted in silico to be benign (p.A650T, p.A932T) and four damaging (p. G171E, p.G776S, p.N831D, p.L895P). Since nine of the novel SNVs occurred only once in the panel, and the other only twice, we were unable to perform further statistical analysis.

Of the reference SNVs, 12 were synonymous and eight were predicted to result in missense amino-acid substitutions (Table 1). Of the eight missense reference SNVs six were predicted to result in damaging amino-acid substitutions—with two occurring in cases only (p.L41V, p. R175C) and three occurring in both cases and controls (p.R721Q, p.R876H, p.R890H). The minor allele frequencies (MAFs) for all reference SNVs found in the cataract case-control panel were similar to those reported in Caucasians by public genome variant databases (Table 1). Four of the synonymous reference SNVs that were relatively common in the Caucasian population (MAF 28%-44%) were also the most common in the cataract case-control panel (S2a Table). However, only one of these SNVs (rs6678616) showed weak association (p = 0.032) with nuclear cataract and nuclear cataract + PSC using Fisher’s Exact Test (S2b Table). Correcting for sex using logistic regression in the association analysis of rs6678616 did not provide significant association with any type of cataract (p > 0.24). The remainder of synonymous reference SNVs occurred in cases and/or controls but were comparatively rare in the panel (MAF < 1%) hampering further statistical analysis.

**Germ-line TP53 variants in the cataract-case control panel**

Exon deep-sequencing of TP53 in the cataract case-control panel detected no novel SNVs and only nine reference SNVs (5 transitions) of which five were also present in the COSMIC database (Table 2 and S3a Table). Two of these SNVs (rs1042522, rs730882008) were non-synonymous and predicted in silico (SIFT) to be damaging, with one (rs1042522, p.P72R) present at relatively high frequency in Caucasians (MAF 0.25) and in multiple cases and controls. However, rs1042522 was not associated with any type of cataract (p > 0.33) using Fisher’s Exact Test (S3b Table). Correcting for sex with logistic regression in the association analysis of rs1042522 did not provide significant association with any type of cataract (p = 0.85). The other SNV (rs730882008, p.R282L) occurred at unknown frequency in the population and in only one case of cortical cataract preventing further statistical analysis.

**Somatic EPHA2 variants in the post-mortem lens panel**

Exon deep-sequencing of EPHA2 in the lens panel detected a total of 935 discordant SNVs (VAF > 1%) in 35 pairs of clear lenses and 726 discordant SNVs in 22 pairs of cataract lenses suggesting a somatic origin (S4 and S5 Tables). We arbitrarily selected a VAF cut-off threshold value of ≥ 3% to minimize false-positive sequencing errors. In the clear lenses, 109 discordant SNVs occurred with a VAF of ≥ 3% in 27 of the 35 clear lens pairs; however, 43 were excluded due to low coverage (read-depth <600). The remaining 66 SNVs, each of which occurred only once in the clear lens pairs, included 28 synonymous SNVs, 32 non-synonymous or missense SNVs resulting in missense substitutions, 3 stop-gain or nonsense SNVs, 2 UTR SNVs, and one splice-site SNV (Table 3). Of these SNVs, only 14 were listed in reference databases (e.g. snp138, cosmic70, exac01) suggesting that 52 were novel somatic SNVs. Of the 32 missense SNVs, only nine were listed in reference databases (e.g. snp138, cosmic70) and 29 were predicted in silico (by the SIFT algorithm) to be damaging (Table 3). Surprisingly, 31 of the 32 missense SNVs involved C/T or G/A transitions and 17 of these occurred at di-pyrimidine sites that are susceptible to UV-induced mutation [60]. Similarly, 18 of the 28 synonymous SNVs along with two UTR SNVs and two nonsense SNVs occurred at UV-susceptible di-pyrimidine sites (Table 3).
Table 2. Germ-line TP53 coding SNVs found in the cataract case-control panel (VAF >20%).

| Exon | Ref. Seq No. | COSMIC ID No. | DNA change | Amino Acid Change | PolyPhen-2 (prediction) | SIFT (prediction) | MAF-EVS Caucasian | MAF—1000G (CEU) | MAF—Cataract Case-Control Panel | Clear Lens | Cortical Cataract | Nuclear Cataract | PSC | Mixed Cataract |
|------|--------------|---------------|------------|-------------------|------------------------|-----------------|------------------|----------------|----------------------------------|------------|----------------|----------------|------|---------------|
| 4    | rs1800370    |               | c.108G>A   | p.P36P            | synonymous             | synonymous       | 0.0148           | 0.0051         | 0.0178              | 2          | 1              | 4              | 1    |               |
| 4    | rs1042522    | COSM250061    | c.215C>G   | p.P72R           | 0.083 (B)              | 0.03 (D)         | 0.2548*          | 0.2424*        | 0.2666*              | 60         | 38             | 64             | 2    | 46            |
| 4    | rs751978853  |               | c.354A>T   | p.T118T          | synonymous             | synonymous       | 0.0022           |               |                     | 1          |                |                |      |               |
| 5    | rs375275361  | COSM45823     | c.558T>C   | p.D186D          | synonymous             | synonymous       | 0.0022           |               |                     | 1          |                |                |      |               |
| 6    | rs1800372    | COSM249885    | c.639A>G   | p.R213R          | synonymous             | synonymous       | 0.0193           | 0.0202         | 0.0333              | 7          | 5              |                | 3    |               |
| 8    | rs770598448  |               | c.789T>C   | p.N263N          | synonymous             | synonymous       | 0.0022           |               |                     | 1          |                |                |      |               |
| 8    | rs730882008  | COSM44470     | c.845G>T   | p.R282L          | 0.998 (D)              | 0.00 (D)         | 0.0022           |               |                     | 1          |                |                |      |               |
| 8    | rs200073907  | COSM45332     | c.885T>C   | p.P295P          | synonymous             | synonymous       | 0.0044           |               |                     | 2          |                |                |      |               |
| 11   | rs765530090  |               | c.1113C>A  | p.S371S          | synonymous             | synonymous       | 0.1800           | 24             | 17                 | 26         | 1              | 13             |      |               |

*MAF refers to reference C allele. (B)—benign, (D)—damaging

https://doi.org/10.1371/journal.pone.0189881.t002
Table 3. Somatic EPHA2 coding SNVs found in the paired clear lens panel (VAF >3%).

| Chr  | Start/End | Ref Allele | Alt Allele | ExonicFunc.refGene | AAChange.refGene | cosmic70 | snp138 | exac01 | SIFT | Depth | VAF  |
|------|-----------|------------|------------|--------------------|------------------|----------|--------|--------|------|-------|------|
| chr1 | 16451690  | G* A*      | UTR-3      | NM_004431:c.*20C>T |                  | 1.58E-05 |        |        |      | 3502  | 3.94%|
| chr1 | 16451707  | G* A*      | UTR-3      | NM_004431:c.*3C>T  |                  |          |        |        |      | 4181  | 3.28%|
| chr1 | 16451720  | A G        | nonsynonymous SNV | EPHA2:NM_004431:exon17.c. T2921C:p.A974T |                |          |        |        |      | 4172  | 3.96%|
| chr1 | 16451809  | G* A*      | synonymous SNV | EPHA2:NM_004431:exon17.c. T2826T:p.D942D rs143828420 | 8.69E-05 | 1416    |        |        |      | 1417  | 4.10%|
| chr1 | 16455972  | C* T*      | nonsynonymous SNV | EPHA2:NM_004431:exon16.c. G2792A:p.A928T |                |          |        |        |      | 3242  | 12.94%|
| chr1 | 16456009  | G* A*      | synonymous SNV | EPHA2:NM_004431:exon16.c. C2745T:p.D942D |                |          |        |        |      | 1416  | 4.10%|
| chr1 | 16456014  | C A        | stopgain    | EPHA2:NM_004431:exon16.c. G2740T:p.E914X ID = COSM3934228 |                |          |        |        |      | 3242  | 8.34%|
| chr1 | 16456016  | A G        | nonsynonymous SNV | EPHA2:NM_004431:exon16.c. G2731A:p.S915S |                |          |        |        |      | 3055  | 13.87%|
| chr1 | 16456023  | C* T*      | nonsynonymous SNV | EPHA2:NM_004431:exon16.c. G2731A:p.E911K |                |          |        |        |      | 7158  | 3.94%|
| chr1 | 16456039  | G* A*      | synonymous SNV | EPHA2:NM_004431:exon16.c. C2715T:p.R905P |                |          |        |        |      | 3055  | 5.24%|
| chr1 | 16456067  | G* A*      | nonsynonymous SNV | EPHA2:NM_004431:exon16.c. C2687T:p.P896L |                |          |        |        |      | 2950  | 5.29%|
| chr1 | 16456074  | C* T*      | synonymous SNV | EPHA2:NM_004431:exon15.c. G2646A:p.K882K |                |          |        |        |      | 4205  | 4.04%|
| chr1 | 16456822  | C A        | nonsynonymous SNV | EPHA2:NM_004431:exon15.c. G2568T:p.Q856H |                |          |        |        |      | 4309  | 7.80%|
| chr1 | 16458240  | G* A*      | synonymous SNV | EPHA2:NM_004431:exon14.c. C2451T:p.P817P |                |          |        |        |      | 6056  | 3.32%|
| chr1 | 16458257  | T C        | nonsynonymous SNV | EPHA2:NM_004431:exon14.c. A2434G:p.T812A |                |          |        |        |      | 5718  | 3.06%|
| chr1 | 16458352  | G* A*      | nonsynonymous SNV | EPHA2:NM_004431:exon14.c. C2339T:p.P817P |                |          |        |        |      | 1668  | 8.69%|
| chr1 | 16458353  | G* A*      | nonsynonymous SNV | EPHA2:NM_004431:exon14.c. C2338T:p.P817S |                |          |        |        |      | 1668  | 5.28%|
| chr1 | 16458579  | C* T*      | nonsynonymous SNV | EPHA2:NM_004431:exon13.c. G2305A:p.E769K |                |          |        |        |      | 1247  | 6.52%|
| chr1 | 16458598  | G A        | synonymous SNV | EPHA2:NM_004431:exon13.c. C2286T:p.R762R |                |          |        |        |      | 2564  | 33.35%|
| chr1 | 16458890  | G* A*      | synonymous SNV | EPHA2:NM_004431:exon12.c. C2098T:p.L700L |                |          |        |        |      | 1776  | 3.72%|
| chr1 | 16458893  | C* T*      | nonsynonymous SNV | EPHA2:NM_004431:exon12.c. G2095A:p.A699T |                |          |        |        |      | 1780  | 4.22%|
| chr1 | 16458896  | C* T*      | nonsynonymous SNV | EPHA2:NM_004431:exon12.c. G2092A:p.G698R |                |          |        |        |      | 1781  | 4.27%|
| chr1 | 16458911  | C* T*      | nonsynonymous SNV | EPHA2:NM_004431:exon12.c. G2077A:p.E693K |                |          |        |        |      | 1776  | 4.23%|
| chr1 | 16458927  | G* A*      | synonymous SNV | EPHA2:NM_004431:exon12.c. C2061T:p.P687P |                |          |        |        |      | 1775  | 3.90%|
| chr1 | 16459729  | T C        | nonsynonymous SNV | EPHA2:NM_004431:exon11.c. A1999G:p.M667V |                |          |        |        |      | 2940  | 8.80%|
| chr1 | 16459977  | T C        | synonymous SNV | EPHA2:NM_004431:exon10.c. A1863G:p.A621A |                |          |        |        |      | 3560  | 3.65%|

(Continued)
| Chr | Start/End | Ref | Alt | ExonicFunc. refGene | AAChange.refGene | cosmic70 | snp138 | exac01 | SIFT | Depth | VAF  |
|-----|-----------|-----|-----|---------------------|------------------|----------|--------|--------|------|-------|------|
| chr1 16460030 | A G nonsynonymous SNV | EPHA2:NM_004431:exon10.c. T1810C:p.F604L | | | | | | | | | |
| chr1 16460049 | G* A* synonymous SNV | EPHA2:NM_004431:exon10.c. C1791T:p.P597P | | | | | | | | | |
| chr1 16460050 | G* A* nonsynonymous SNV | EPHA2:NM_004431:exon10.c. C1790T:p.P597L | | | | | | | | | |
| chr1 16460066 | G* A* nonsynonymous SNV | EPHA2:NM_004431:exon10.c. C1774T:p.P597P | | | | | | | | | |
| chr1 16460068 | G* A* nonsynonymous SNV | EPHA2:NM_004431:exon10.c. C1772T:p.P597L | | | | | | | | | |
| chr1 16460401 | G* A* synonymous SNV | EPHA2:NM_004431:exon9.c. C1692T:p.N564N | | | | | | | | | |
| chr1 16460407 | C* T* synonymous SNV | EPHA2:NM_004431:exon9.c. G1686A:p.R562R | | | | | | | | | |
| chr1 16460962 | C* T* splicing | NM_004431:exon9.c.1682 +1G > A | | | | | | | | | |
| chr1 16461003 | G* A* nonsynonymous SNV | EPHA2:NM_004431:exon8.c. C1642T:p.L548F | | | | | | | | | |
| chr1 16461007 | G* A* synonymous SNV | EPHA2:NM_004431:exon8.c. C1638T:p.V541M | | | | | | | | | |
| chr1 16461024 | C T nonsynonymous SNV | EPHA2:NM_004431:exon8.c. G1621A:p.V541M | | | | | | | | | |
| chr1 16462157 | C T nonsynonymous SNV | EPHA2:NM_004431:exon6.c. G1421A:p.R474H | | | | | | | | | |
| chr1 1644354 | G* A* stopgain | EPHA2:NM_004431:exon5.c. C1480G:p.R474X | | | | | | | | | |
| chr1 1646480 | G* A* nonsynonymous SNV | EPHA2:NM_004431:exon5.c. C1180T:p.R359C | | | | | | | | | |
| chr1 1646490 | G A synonymous SNV | EPHA2:NM_004431:exon5.c. C1170T:p.H359H | | | | | | | | | |
| chr1 1646498 | G* A* nonsynonymous SNV | EPHA2:NM_004431:exon5.c. C1162T:p.R359S | | | | | | | | | |
| chr1 16464513 | C T nonsynonymous SNV | EPHA2:NM_004431:exon5.c. G1064A:p.G355E | | | | | | | | | |
| chr1 1646529 | C* T* synonymous SNV | EPHA2:NM_004431:exon5.c. G1034A:p.D348E | | | | | | | | | |
| chr1 1646550 | C* T* stopgain | EPHA2:NM_004431:exon5.c. G1010A:p.W337X | | | | | | | | | |
| chr1 1646553 | G* A* synonymous SNV | EPHA2:NM_004431:exon5.c. C1077T:p.C359C | | | | | | | | | |
| chr1 1646583 | G A synonymous SNV | EPHA2:NM_004431:exon5.c. C1077T:p.D339D | | | | | | | | | |
| chr1 1646596 | C* T* nonsynonymous SNV | EPHA2:NM_004431:exon5.c. G1064A:p.G355E | | | | | | | | | |
| chr1 1646607 | A G synonymous SNV | EPHA2:NM_004431:exon5.c. T1053C:p.P351P | | | | | | | | | |
| chr1 1646618 | A G nonsynonymous SNV | EPHA2:NM_004431:exon5.c. T1042C:p.W348R | | | | | | | | | |
| chr1 1646621 | G A nonsynonymous SNV | EPHA2:NM_004431:exon5.c. C1039T:p.R347C | | | | | | | | | | 7.90E-06 | |
| chr1 1646625 | C* T* synonymous SNV | EPHA2:NM_004431:exon5.c. G1035A:p.E345E | | | | | | | | | | |

(Continued)
In the cataract lenses, 35 discordant EPHA2 SNVs occurred with a VAF ≥ 3% in 10 of the 22 cataract lens pairs with only two excluded due to low read-depth (S5 Table). The remaining 33 singly occurring SNVs included 12 synonymous SNVs, 19 non-synonymous or missense SNVs, and two stop-gain or nonsense SNVs (Table 4). Of these SNVs, six were present in reference databases suggesting that 27 were novel somatic SNVs and only one (at position 16460407 bp) was present in both cataract and clear lenses (Tables 3 and 4). Of the 19 missense SNVs only four were present in reference databases and 15 were predicted in silico (SIFT) to be damaging (Table 4). All 19 missense SNVs involved C/T or A/G transitions and 12 of these occurred at UV-susceptible di-pyrimidine sites. Ten of the 12 synonymous SNVs and both nonsense SNVs also occurred at UV-susceptible di-pyrimidine sites. Overall for EPHA2, there was no significant difference between the paired clear lens panel and the paired cataract lens panel with respect to total SNVs ($p = 0.48$), damaging SNVs ($p = 0.85$), or novel SNVs ($p = 0.64$) using Fisher’s Exact Test (S6 Table). Correcting for sex in the lens panels using logistic regression analysis did not provide any significant association for total EPHA2 SNVs ($p = 0.62$), damaging EPHA2 SNVs ($p = 0.63$), or novel EPHA2 SNVs ($p = 0.70$).

Somatic TP53 variants in the post-mortem lens panel

Exon deep-sequencing of TP53 in the lens panel detected a total of 392 discordant SNVs (VAF > 1%) in 35 clear lens pairs and 298 discordant SNVs in 22 cataract lens pairs (S7 and

### Table 3. (Continued)

| Chr | Start/End | Ref | Alt | ExonicFunc.refGene | AAChange.refGene | cosmic70 | snp138 | exact01 | SIFT | Depth | VAF  |
|-----|-----------|-----|-----|-------------------|-----------------|----------|--------|--------|------|-------|------|
| chr1 | 16464641 | A   | G   | nonsynonymous SNV | EPHA2:NM_004431:exon5:c. T1019C:p.M340T | D        | 1011   | 4.95%  |
| chr1 | 16464655 | G*  | A*  | synonymous SNV    | EPHA2:NM_004431:exon5:c. C1005T:p.L335L |          | 2505   | 4.47%  |
| chr1 | 16464658 | G*  | A*  | synonymous SNV    | EPHA2:NM_004431:exon5:c. C1002T:p.Y334Y |          | 2078   | 8.81%  |
| chr1 | 16464664 | T   | C   | synonymous SNV    | EPHA2:NM_004431:exon5:c. A996G:p.P332P |          | 2070   | 3.54%  |
| chr1 | 16464822 | A   | G   | synonymous SNV    | EPHA2:NM_004431:exon4:c. T927C:p.C309C |          | 6671   | 3.36%  |
| chr1 | 16475091 | G*  | A*  | nonsynonymous SNV | EPHA2:NM_004431:exon3:c. C605T:p.P202L | D        | 3906   | 4.74%  |
| chr1 | 16475108 | G*  | A*  | synonymous SNV    | EPHA2:NM_004431:exon3:c. C588T:p.V196V |          | 3928   | 3.39%  |
| chr1 | 16475144 | A   | G   | synonymous SNV    | EPHA2:NM_004431:exon3:c. T552C:p.D184D |          | 2676   | 10.31% |
| chr1 | 16475374 | A   | G   | nonsynonymous SNV | EPHA2:NM_004431:exon3:c. T322C:p.F108L | rs149867517 | 7.89E-06 | T     | 5817  | 4.06% |
| chr1 | 16475408 | A   | G   | synonymous SNV    | EPHA2:NM_004431:exon3:c. T288C:p.I96I |          | 4013   | 12.52% |
| chr1 | 16475446 | T   | C   | nonsynonymous SNV | EPHA2:NM_004431:exon3:c. A250G:p.N84D | T        | 5681   | 3.15%  |
| chr1 | 16475451 | C   | T   | nonsynonymous SNV | EPHA2:NM_004431:exon3:c. G245A:p.R82H | 1.58E-05  | D     | 5662  | 3.55% |
| chr1 | 16477406 | G*  | A*  | synonymous SNV    | EPHA2:NM_004431:exon2:c. C138T:p.H46H | 7.89E-06  | 4868  | 4.36%  |

*SNV at di-pyrimidine site. D—damaging, T—tolerated.

https://doi.org/10.1371/journal.pone.0189881.t003
Table 4. Somatic *EPHA2* coding SNVs found in the paired cataract lens panel (VAF >3%).

| Chr | Start/End | Ref | Alt | ExonicFunc.refGene | AAChange.refGene | cosmic70 | snp138 | exac01 | SIFT | Depth | VAF |
|-----|-----------|-----|-----|-------------------|-----------------|----------|--------|-------|------|-------|-----|
| chr1 | 16456045  | C* | T* | synonymous SNV    | EPHA2:NM_004431:exon16:c. G2709A:p.G903G | 1.58E-05 | T      | 3596  | 3.81%|
| chr1 | 16456068  | G* | A* | nonsynonymous SNV | EPHA2:NM_004431:exon16:c. C2686T:p.P896S | T        | 2885  | 5.03%|
| chr1 | 16456083  | C  | T  | nonsynonymous SNV | EPHA2:NM_004431:exon16:c. G2671A:p.V891M | rs139168333 | T | 3220 | 3.63%|
| chr1 | 16456749  | G* | A* | nonsynonymous SNV | EPHA2:NM_004431:exon15:c. C2641T:p.L881F | D        | 3694  | 6.37%|
| chr1 | 16456804  | G* | A* | synonymous SNV    | EPHA2:NM_004431:exon15:c. C2586T:p.P862P | D        | 5679  | 4.19%|
| chr1 | 16456871  | A  | G  | nonsynonymous SNV | EPHA2:NM_004431:exon15:c. T2519C:p.M840T | D        | 1851  | 3.08%|
| chr1 | 16458249  | G  | A  | synonymous SNV    | EPHA2:NM_004431:exon14:c. C2442T:p.G814G | 5698     | 8.80%|
| chr1 | 16458309  | G* | A* | synonymous SNV    | EPHA2:NM_004431:exon14:c. C2382T:p.F794F | 3319    | 6.03%|
| chr1 | 16458692  | G* | A* | nonsynonymous SNV | EPHA2:NM_004431:exon13:c. C2192T:p.A731V | D        | 3645  | 4.49%|
| chr1 | 16458703  | C* | T* | nonsynonymous SNV | EPHA2:NM_004431:exon13:c. G2121A:p.K707A | D        | 2735  | 4.64%|
| chr1 | 16458763  | C* | T* | synonymous SNV    | EPHA2:NM_004431:exon11:c. G1881A:p.V627V | 3151    | 4.25%|
| chr1 | 16460407  | C* | T* | synonymous SNV    | EPHA2:NM_004431:exon9:c. G1686A:p.R562R | 2620    | 3.32%|
| chr1 | 16462261  | G* | A* | synonymous SNV    | EPHA2:NM_004431:exon6:c. C1317T:p.P439P | T        | 3943  | 3.61%|
| chr1 | 1646353   | T  | C  | nonsynonymous SNV | EPHA2:NM_004431:exon5:c. A1307G:p.O436R | D        | 2232  | 6.14%|
| chr1 | 1646466   | T  | C  | nonsynonymous SNV | EPHA2:NM_004431:exon5:c. A1060G:p.S354G | D        | 1669  | 4.38%|
| chr1 | 1646468   | G* | A* | nonsynonymous SNV | EPHA2:NM_004431:exon5:c. C1052T:p.P351L | D        | 1669  | 4.38%|
| chr1 | 1646469   | G* | A* | nonsynonymous SNV | EPHA2:NM_004431:exon5:c. C1051T:p.P351S | D        | 2969  | 4.65%|
| chr1 | 16464610  | G* | A* | synonymous SNV    | EPHA2:NM_004431:exon5:c. C1050G:p.P350P | D        | 3004  | 4.23%|
| chr1 | 16464614  | G  | A  | nonsynonymous SNV | EPHA2:NM_004431:exon5:c. C1046T:p.T349M | rs200490325 | 2.37E-04 | D | 3066 | 4.08%|
| chr1 | 16464617  | C* | T* | stopgain          | EPHA2:NM_004431:exon5:c. G1043A:p.W348X | T        | 2426  | 6.84%|
| chr1 | 16464623  | A  | G  | nonsynonymous SNV | EPHA2:NM_004431:exon5:c. T1037C:p.L346P | 7.99E-06 | D | 2780 | 3.42%|
| chr1 | 16464624  | G* | A* | synonymous SNV    | EPHA2:NM_004431:exon5:c. T1036C:p.L346L | 1668     | 4.62%|
| chr1 | 16464633  | T  | C  | nonsynonymous SNV | EPHA2:NM_004431:exon5:c. A1027G:p.K343E | D        | 2716  | 3.57%|
| chr1 | 16464665  | G* | A* | nonsynonymous SNV | EPHA2:NM_004431:exon5:c. C995T:p.P332L | D        | 1708  | 4.64%|
| chr1 | 16464666  | G* | A* | nonsynonymous SNV | EPHA2:NM_004431:exon5:c. C994T:p.P332S | D        | 1698  | 4.71%|

(Continued)
In the clear lenses, 64 discordant SNVs were present at a VAF > 3% in 27 of the 35 pairs; however, 12 of these SNVs were excluded due to low read-depth (< 600). In addition, three discordant SNVs occurred more than once—one non-synonymous SNV (COSM1658764) occurred in nine lenses, one synonymous SNV (present in ExAC01) occurred in 11 lenses, and one UTR SNV occurred in two lenses—resulting in a total of 19 SNVs that were excluded for recurrence. The remaining 33 single occurrence SNVs included nine synonymous SNVs (8 transitions), 16 non-synonymous or missense SNVs (15 transitions), seven UTR SNVs (all transitions), and one splicing SNV (transition). Of these SNVs, 18 were present in reference databases (e.g. cosmic, snp138, exac01) leaving 15 putatively novel somatic SNVs (S7d Table). Of the 16 missense SNVs, 13 were present in reference databases, six were predicted in silico (SIFT) to be damaging, and five occurred at UV-susceptible di-pyrimidine sites. Apart from the splicing SNV, none of the synonymous SNVs or UTR SNVs occurred at di-pyrimidine sites (S7d Table).

In the cataract lenses, 18 discordant TP53 SNVs (all transitions) occurred with VAFs > 3% in five of the 22 pairs of lenses including five synonymous SNVs, 12 non-synonymous or missense SNVs, and one UTR-3’ SNV (S8d Table). Of these single occurrence SNVs, 12 were present in reference databases (e.g. cosmic, snp138, exac01) leaving 15 putatively novel somatic SNVs (S7d Table). Of the 16 missense SNVs, 13 were present in reference databases, seven were predicted to be damaging, and five occurred at UV-susceptible di-pyrimidine sites. Apart from the splicing SNV, none of the synonymous SNVs or UTR SNVs occurred at di-pyrimidine sites (S7d Table).

Overall for TP53, there was no significant difference between the paired clear lens panel and the paired cataract lens panel with respect to total SNVs (p = 0.73), damaging SNVs (p = 0.77), or novel SNVs (p = 0.78) using Fisher’s Exact Test (S9 Table). Correcting for sex in the lens panels using logistic regression analysis did not provide any significant association for total TP53 SNVs (p = 0.39), damaging TP53 SNVs (p = 0.71), or novel TP53 SNVs (p = 0.57).

Discussion

In this study we utilized targeted-amplicon (exon) deep-sequencing to identify germ-line and somatic variants of EPHA2—particularly novel missense variants predicted in silico to result in

| Chr | Start/End | Ref | Alt | ExonicFunc. refGene | AAChange.refGene | cosmic70 | snp138 | excac01 | SIFT | Depth | VAF |
|-----|--------|-----|-----|---------------------|------------------|---------|--------|---------|------|-------|-----|
| chr1 | 16464790 | G* | A* | nonsynonymous SNV | EPHA2:NM_004431:exon4:c. C959T:p.P320L | T | 6624 | 3.30% |
| chr1 | 16464917 | G* | A* | nonsynonymous SNV | EPHA2:NM_004431:exon4:c. C832T:p.P278S | ID = COSM1185338 | T | 602 | 3.49% |
| chr1 | 16474897 | C* | T* | nonsynonymous SNV | EPHA2:NM_004431:exon3:c. G799A:p.E267K | D | 2893 | 6.22% |
| chr1 | 16475162 | G* | A* | synonymous SNV | EPHA2:NM_004431:exon3:c. C534T:p.F178F | | 6441 | 3.46% |
| chr1 | 16475177 | G* | A* | synonymous SNV | EPHA2:NM_004431:exon3:c. C519T:p.L173P | 2.37E-05 | 5784 | 3.46% |
| chr1 | 16475269 | C* | T* | nonsynonymous SNV | EPHA2:NM_004431:exon3:c. G427A:p.D143N | D | 3573 | 8.28% |
| chr1 | 16475541 | C* | T* | stopgain | EPHA2:NM_004431:exon3:c. G155A:p.W52X | T | 3510 | 7.67% |

*SNV at di-pyrimidine site. D—damaging, T—tolerated.

https://doi.org/10.1371/journal.pone.0189881.t004
deleterious amino-acid substitutions—that may be associated with lens aging and/or age-related cataract. First, we profiled germ-line SNVs (VAF > 20%) in EPHA2 for association with age-related cataract in a Caucasian case-control panel that had previously revealed association with common reference SNVs flanking EPHA2 [30]. Exon deep-sequencing detected six novel missense SNVs and eight reference missense SNVs in the cataract case-control panel that were predicted to be damaging (Table 1). However, the relatively small number of individuals in the cataract case-control panel that harbored these damaging EPHA2 SNVs (n < 20) limited the power of this study to detect disease association. For example, of two novel SNVs located in the extracellular LBD of EPHA2 one (p.I142T) was present in a control, while the other (p.G171E) occurred in a case with cortical cataract. Similarly, one of the reference missense SNVs, rs116506614 (c.2162G>A, p.R721Q), located in the TK domain of EPHA2, that has previously been associated with age-related cortical cataract [26], was present in a case with cortical cataract and in a control from our cataract case-control panel. Overall, while it is possible that such control individuals may be pre-symptomatic for age-related cataract, we note that other putatively deleterious SNVs were found only in controls, whereas, putatively benign SNVs were present in cases (Table 1) rendering simple genotype-phenotype correlations inconclusive.

Second, we profiled putative somatic SNVs in EPHA2 (VAF ≥ 3%) that arose in post-mortem lenses procured from Caucasian donors over 48 years of age (Tables 3 and 4). Paired analysis of right and left lenses from the same individual for discordant SNVs, analogous to that of matched tumor versus control tissues, detected 19 novel missense SNVs in a clear lens panel (35 pairs) and 13 novel missense SNVs in a cataract lens panel (22 pairs) that were predicted to be damaging (Tables 3 and 4). By comparison, the same paired-lens analysis of TP53 for discordant SNVs yielded predominantly reference somatic SNVs found in the COSMIC database and no novel SNVs that were predicted to be damaging (S7 and S8 Tables). This difference in SNV profile between the two genes likely reflects the high frequency of somatic mutations identified in TP53 versus EPHA2. Currently, the COSMIC database lists over 29,480 somatic mutations in TP53 including 17,166 missense substitutions that have been detected in multiple tumor samples (e.g. cutaneous melanoma) at relatively high frequencies (~27%). By contrast, EPHA2 harbors some 275 somatic mutations including 164 missense substitutions that have been detected in multiple tumor samples (e.g. stomach, intestine, skin), at relatively low frequencies (typically < 5%) (http://cancer.sanger.ac.uk/cosmic). These observations suggest that novel somatic variants in EPHA2 that are predicted to be functionally deleterious are detectable in aging human lenses. Overall, our data are in agreement with a recent study that employed targeted-hybridization deep-sequencing of human lens epithelial samples to identify somatic variants in a panel of 151 cancer-related genes [61]. To the best of our knowledge, this is the first report of putative somatic mutations in a lens-expressed gene causally implicated in age-related cataract. However, since rudimentary statistical analysis confirmed that somatic SNVs in EPHA2 were present at comparable frequencies in both clear lenses and those with age-related cataract we are unable to determine if such variants are causative for disease.

A striking feature of both the germ-line and the somatic missense SNVs in EPHA2 detected here was the high frequency of transitions (C/T, G/A) versus transversions (G/C, G/T, A/C, A/T). Theoretically, transversions should occur twice as often as transitions; however, a review of the germ-line variation annotated in the EPHA2 reference sequence reveals that the vast majority of missense variants involve C/T or G/A transitions (http://www.ncbi.nlm.nih.gov/variation/view/). The occurrence of somatic C>T transitions is of particular interest since they may result from exposure to solar UV radiation [60]. Absorption of solar UV radiation (95% UV-A, 5% UV-B) by DNA promotes the formation of photodimeric lesions, mostly cyclobutane pyrimidine dimers (CPDs), at adjacent pyrimidine bases (C and T) that may escape
nucleotide excision repair leading to base substitution and generation of UV-signature mutations (C>T or CC>TT) during DNA replication [62]. Among the somatic missense SNVs detected in our lens panel (clear and cataract) many of the C>T changes (G>A on the complementary strand) were present at di-pyrimidine (diPy) sites (CT, TC, CC) in both EPHA2 and TP53 raising the possibility that they represent UV-signature mutations (Tables 3 and 4 and S7 and S8 Tables). While there was no significant association between these somatic SNVs and cataract in our lens panel, epidemiological studies have established that lifetime exposure to solar UV radiation (particularly UV-B) is a significant risk factor for cortical cataract particularly within the lens nasal quadrant [63,64]. In addition, UV-A radiation has been implicated in the increased prevalence of left-sided cortical cataract and facial skin cancer, likely in part, due to increased exposure while operating left-hand drive vehicles [65]. Further, it has been suggested that oxidative stress secondary to solar UV exposure might contribute to age-related cataract [66]. However, since the cornea effectively absorbs most solar UV-B radiation (290–320 nm) and the levels of CPDs in lens epithelia obtained from cataract patients has been reported to be relatively low compared to those of oxidized purines, the cause-effect relationship between solar UV exposure and age-related cataract remains unclear [67,68]. Future studies of somatic variants, including UV-signature mutations, in EPHA2 and over 30 other known cataract genes, including those for crystallins (e.g. CRYAA), connexins (e.g. GJA8) and ocular transcription factors (e.g. HSF4) [14,15] may provide new insights regarding the molecular genetic mechanisms underlying age-related cataract.

Supporting information

S1 Table. Amplicon deep-sequencing coverage in the cataract case-control panel (a) and the post-mortem lens panel (b).
(XLSX)

S2 Table. Germ-line EPHA2 coding SNV frequency (a) and association (b) in the cataract case-control panel (VAF >20%).
(XLSX)

S3 Table. Germ-line TP53 coding SNV frequency (a) and association (b) in the cataract case-control panel (VAF >20%).
(XLSX)

S4 Table. Somatic EPHA2 coding SNVs found in the paired clear lens panel.
(XLSX)

S5 Table. Somatic EPHA2 coding SNVs found in the paired cataract lens panel.
(XLSX)

S6 Table. Fisher’s exact test of EPHA2 coding SNVs found in the post-mortem lens panel.
(XLSX)

S7 Table. Somatic TP53 coding SNVs found in the paired clear lens panel.
(XLSX)

S8 Table. Somatic TP53 coding SNVs found in the paired cataract lens panel.
(XLSX)

S9 Table. Fisher’s exact test of TP53 coding SNVs found in the post-mortem lens panel.
(XLSX)
Acknowledgments

We thank the Genome Technology Access Center (GTAC) at Washington University School of Medicine for help with amplicon deep-sequencing and variant analysis.

Author Contributions

Conceptualization: J. Fielding Hejtmancik, Alan Shiels.

Data curation: Thomas M. Bennett, Alan Shiels.

Formal analysis: Thomas M. Bennett, Oussama M’Hamdi, J. Fielding Hejtmancik, Alan Shiels.

Funding acquisition: Alan Shiels.

Investigation: Thomas M. Bennett, Alan Shiels.

Project administration: Alan Shiels.

Resources: J. Fielding Hejtmancik, Alan Shiels.

Supervision: J. Fielding Hejtmancik, Alan Shiels.

Validation: Thomas M. Bennett, Alan Shiels.

Visualization: Thomas M. Bennett, Oussama M’Hamdi, J. Fielding Hejtmancik, Alan Shiels.

Writing – original draft: Alan Shiels.

Writing – review & editing: J. Fielding Hejtmancik, Alan Shiels.

References

1. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012; 96 (5):614–618. PMID: 22133988. https://doi.org/10.1136/bjophthalmol-2011-300539

2. Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013; 1(6):e339–349. PMID: 25104599. https://doi.org/10.1016/S2214-109X(13)70113-X

3. Khairallah M, Kahloun R, Bourne R, Limburg H, Flaxman SR, Jonas JB, et al. Number of People Blind or Visually Impaired by Cataract Worldwide and in World Regions, 1990 to 2010. Invest Ophthalmol Vis Sci. 2015; 56(11):6762–6769. PMID: 26567788. https://doi.org/10.1167/iovs.15-17201

4. West SK, Valmadrict ET. Epidemiology of risk factors for age-related cataract. Surv Ophthalmol. 1995; 39(4):323–334. PMID: 7725232.

5. Hodge WG, Whitcher JP, Satariano W. Risk factors for age-related cataracts. Epidemiol Rev. 1995; 17 (2):336–346. PMID: 8654515.

6. Taylor HR. Epidemiology of age-related cataract. Eye (Lond). 1999; 13 (Pt 3b):445–448.

7. McCarty CA, Taylor HR. The genetics of cataract. Invest Ophthalmol Vis Sci. 2001; 42(8):1677–1678. PMID: 11431427.

8. Sanfilippo PG, Hewitt AW, Hammond CJ, Mackey DA. The heritability of ocular traits. Surv Ophthalmol. 2010; 55(6):561–583. PMID: 20851442. https://doi.org/10.1016/j.survophthal.2010.07.003

9. Foster A, Gilbert C, Rahi J. Epidemiology of cataract in childhood: a global perspective. J Cataract Refract Surg. 1997; 23 Suppl 1:601–604. PMID: 9278811.

10. Haaggaard B, Wohlfahrt J, Fledelius HC, Rosenberg T, Melbye M. A nationwide Danish study of 1027 cases of congenital/infantile cataracts: etiological and clinical classifications. Ophthalmology. 2004; 111 (12):2292–2298. PMID: 15582089. https://doi.org/10.1016/j.ophtha.2004.06.024

11. Lim Z, Rubab S, Chan YH, Levin AV. Pediatric cataract: the Toronto experience-etiology. Am J Ophthalmol. 2010; 149(6):887–892. PMID: 20430363. https://doi.org/10.1016/j.ajo.2010.01.012

12. Kong L, Fry M, Al-Samarraie M, Gilbert C, Steinkuller PG. An update on progress and the changing epidemiology of causes of childhood blindness worldwide. J AAOPOS. 2012; 16(6):501–507. PMID: 23237744. https://doi.org/10.1016/j.jaapos.2012.09.004
13. Rahi JS, Dezateux C. Congenital and infantile cataract in the United Kingdom: underlying or associated factors. British Congenital Cataract Interest Group. Invest Ophthalmol Vis Sci. 2000; 41(8):2108–2114. PMID: 10892851.

14. Shiels A, Bennett TM, Hejtmancik JF. Cat-Map: putting cataract on the map. Mol Vis. 2010; 16:2007–2015. PMID: 21042563.

15. Shiels A, Hejtmancik JF. Mutations and mechanisms in congenital and age-related cataracts. Exp Eye Res. 2016; 156:95–102. PMID: 27334249. https://doi.org/10.1016/j.exer.2016.06.011

16. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell. 2008; 133(1):38–52. PMID: 18394988. https://doi.org/10.1016/j.cell.2008.03.011

17. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010; 10(3):165–180. PMID: 20179713. https://doi.org/10.1038/nrc2806

18. Lisabeth EM, Falivelli G, Pasquale EB. Eph receptor signaling and ephrins. Mol Vis. 2010; 16:2007–2015. PMID: 21042563.

19. Barquilla A, Pasquale EB. Eph receptors and ephrins: therapeutic opportunities. Ann Rev Pharmacol Toxicol. 2015; 55:465–487. PMID: 27334249. https://doi.org/10.1146/annurev-pharmtox-011112-140226

20. Kania A, Klein R. Mechanisms of ephrin-Eph signalling in development, physiology and disease. Nat Rev Mol Cell Biol. 2016; 17(4):240–256. PMID: 26790531. https://doi.org/10.1038/nrm.2015.16

21. Stapleton D, Balan I, Pawson T, Sisler F. The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization. Nat Struct Biol. 1999; 6(1):44–49. PMID: 9886291. https://doi.org/10.1038/4917

22. Lee HJ, Hota PK, Chugha P, Guo H, Miao H, Zhang L, et al. NMR structure of a heterodimeric SAM:SAM complex: characterization and manipulation of EphA2 binding reveals new cellular functions of SHIP2: Structure. 2012; 20(1):41–55. PMID: 22244754. https://doi.org/10.1016/j.str.2011.11.013

23. Lindberg RA, Hunter T. cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol Cell Biol. 1990; 10(12):6316–6324. PMID: 2174105.

24. Bassnett S, Wilmarth PA, David LL. The membrane proteome of the mouse lens fiber cell. Mol Vis. 2009; 15:2448–2463. PMID: 19956408.

25. Wang Z, Han J, David LL, Schey KL. Proteomics and phosphoproteomics analysis of human lens fiber cell membranes. Invest Ophthalmol Vis Sci. 2013; 54(2):1135–1143. PMID: 23349431. https://doi.org/10.1177/ios.12-11168

26. Jun G, Guo H, Klein BE, Klein R, Wang JJ, Mitchell P, et al. EPHA2 is associated with age-related cortical cataract in mice and humans. PLoS Genetics. 2009; 5(7):e1000584. PMID: 19649315. https://doi.org/10.1371/journal.pgen.1000584

27. Cheng C, Gong X. Diverse roles of Eph/ephrin signaling in the mouse lens. PLoS One. 2011; 6(11):e28147. PMID: 22140528. https://doi.org/10.1371/journal.pone.0028147

28. Shi Y, De Maria A, Bennett T, Shiels A, Bassnett S. A role for epha2 in cell migration and refractive organization of the ocular lens. Invest Ophthalmol Vis Sci. 2012; 53(2):551–559. PMID: 22167091. https://doi.org/10.1177/ios.11-8568

29. Cheng C, Ansari MM, Cooper JA, Gong X. EphA2 and Src regulate equatorial cell morphogenesis during lens development. Development. 2013; 140(20):4237–4245. PMID: 24026120. https://doi.org/10.1242/dev.100727

30. Shiels A, Bennett TM, Knopf HL, Maraini G, Li A, Jiao X, et al. The EPHA2 gene is associated with cataracts linked to chromosome 1p. Mol Vis. 2008; 14:2042–2055. PMID: 19005574.

31. Zhang T, Hua R, Xiao W, Burdon KP, Bhattarcharya SS, Craig JE, et al. Mutations of the EPHA2 receptor tyrosine kinase gene cause autosomal dominant congenital cataract. Hum Mutat. 2009; 30(5):E603–611. PMID: 19306328. https://doi.org/10.1002/humu.20995

32. Kaul H, Riazuddin SA, Shahid M, Kousar S, Butt NH, Zafar AU, et al. Autosomal recessive congenital cataract linked to EPHA2 in a consanguineous Pakistani family. Mol Vis. 2010; 16:511–517. PMID: 20361013.

33. Aldahmesh MA, Khan AO, Mohamed JY, Hijazi H, Al-Owain M, Alsawai A, et al. Genomic analysis of pediatric cataract in Saudi Arabia reveals novel candidate disease genes. Genet Med. 2012; 14(12):995–962. PMID: 22935719. https://doi.org/10.1038/gim.2012.86

34. Shentu XC, Zhao SJ, Zhang L, Miao Q. A novel p.R890C mutation in EPHA2 gene associated with progressive childhood posterior cataract in a Chinese family. Int J Ophthalmol. 2013; 6(1):34–38. PMID: 23447127. https://doi.org/10.3980/j.issn.2222-3959.2013.01.07
35. Dave A, Laurie K, Staffieri SE, Taranath D, Mackey DA, Mitchell P, et al. Mutations in the EPHA2 gene are a major contributor to inherited cataracts in South-Eastern Australia. PLoS One. 2013; 8(8):e72518. PMID: 24014202. https://doi.org/10.1371/journal.pone.0072518

36. Gillespie RL, O’Sullivan J, Ashworth J, Bhaskar S, Williams S, Biswas S, et al. Personalized diagnosis and management of congenital cataract by next-generation sequencing. Ophthalmology. 2014; 121 (11):2124–2137 e1–2. PMID: 25148791. https://doi.org/10.1016/j.ophtha.2014.06.006

37. Sun W, Xiao X, Li S, Guo X, Zhang Q. Exome sequencing of 18 Chinese families with congenital cataracts: a new sight of the NHS gene. PLoS one. 2014; 9(6):e100455. PMID: 24968223. https://doi.org/10.1371/journal.pone.0100455

38. Bu J, He S, Wang L, Li J, Liu J, Zhang X. A novel splice donor site mutation in EPHA2 caused congenital cataract in a Chinese family. Ind J Ophthalmol. 2016; 64(5):364–368. PMID: 27380975. https://doi.org/10.4103/0301-4738.185597

39. Reis LM, Tyler RC, Semina EV. Identification of a novel C-terminal extension mutation in EPHA2 in a family affected with congenital cataract. Mol Vis. 2014; 20:836–842. PMID: 24940039.

40. Park JE, Son AI, Hua R, Wang L, Zhang X, Zhou R. Human cataract mutations in EPHA2 SAM domain and managemen t of congenital cataract by next-generation sequencing. Ophthalmology. 2014; 121(11):2124–2137 e1–2. PMID: 25148791. https://doi.org/10.1016/j.ophtha.2014.06.006

41. Patel N, Anand D, Monies D, Maddirevula S, Khan AO, Algoufi T, et al. Novel phenotypes and loci identified through clinical genomics approaches to pediatric cataract. Hum Genet. 2017; 136:205–225. PMID: 27878435. https://doi.org/10.1007/s00439-016-1747-6

42. Musleh M, Hall G, Lloyd IC, Gillespie RL, Waller S, Douzgou S, et al. Diagnosing the cause of bilateral paediatric cataracts: comparison of standard testing with a next-generation sequencing approach. Eye (Lond) 2016; 30:1175–1181. PMID: 27315345. https://doi.org/10.1038/eye.2016.105

43. Chen J, Wang Q, Cabrera PE, Zhong Z, Sun W, jiao X, et al. Molecular genetic analysis of Pakistani families with autosomal recessive congenital cataracts by homozygosity screening. Invest Ophthalmol Vis Sci. 2017; 58:2207–2217. PMID: 28418495. https://doi.org/10.1167/iovs.17-21469

44. Yang J, Luo J, Zhou P, Cai L, Qiu X, Zhou P, et al. The Polymorphisms with Cataract Susceptibility Impair EPHA2 Receptor Stability and Its Cytoprotective Function. J Ophthalmol. 2015; 2015:401894. PMID: 26664742. https://doi.org/10.1155/2015/401894

45. Li D, Wang S, Ye H, Tang Y, Qiu X, Fan Q, et al. Distribution of gene mutations in sporadic congenital cataract in a Han Chinese population. Mol Vis. 2016; 22:589–598. PMID: 27307692.

46. Patel N, Anand D, Monies D, Maddirevula S, Khan AO, Algoufi T, et al. Novel phenotypes and loci identified through clinical genomics approaches to pediatric cataract. Hum Genet. 2017; 136:205–225. PMID: 27878435. https://doi.org/10.1007/s00439-016-1747-6

47. Sundaresan P, Ravindran RD, Vashist P, Shanker A, Nitsch D, Talwar B, et al. EPHA2 polymorphisms and age-related cataract in India. PLoS One. 2012; 7(3):e33001. PMID: 22412971. https://doi.org/10.1371/journal.pone.0033001

48. Yang J, Luo J, Zhou P, Fan Q, Luo Y, Lu Y. Association of the eph receptor tyrosinekinase-type A2 (EPHA2) gene polymorphism rs3754334 with age-related cataract risk: a meta-analysis. PLoS One. 2013; 8(8):e71003. PMID: 23976972. https://doi.org/10.1371/journal.pone.0071003

49. Celojevic D, Abramsson A, Seibt Palmer M, Tasa G, Juronen E, Zetterberg H, et al. EPHA2 Polymorphisms in Estonian Patients with Age-Related Cataract. Ophthal Genet. 2016; 37(1):14–18. PMID: 24673449. https://doi.org/10.3109/13816810.2014.902080

50. Zhang H, Zhong J, Bian Z, Fang X, Peng Y, Hu Y. Association between polymorphisms of OGG1, EPHA2 and age-related cataract risk: a meta-analysis. BMC Ophthalmol. 2016; 16(1):168. PMID: 27681698. https://doi.org/10.1186/s12886-016-0341-y

51. Masoodi TA, Shammari SA, Al-Muammar MN, Alhmadan AA. Screening and structural evaluation of deleterious Non-Synonymous SNPs of ePHA2 gene involved in susceptibility to cataract formation. Bioinformation. 2012; 8(12):562–567. PMID: 22829731. https://doi.org/10.6026/97320630008562

52. Yang J, Li D, Fan Q, Cai L, Qiu X, Zhou P, et al. The Polymorphisms with Cataract Susceptibility Impair the EPHA2 Receptor Stability and Its Cytoprotective Function. J Ophthalmol. 2015; 2015:401894. PMID: 26664742. https://doi.org/10.1155/2015/401894

53. Clinical Trial of Nutritional S, Age-Related Cataract Study G, Maraini G, Williams SL, Sperduto RD, Ferris F, et al. A randomized, double-masked, placebo-controlled clinical trial of multivitamin supplementation for age-related lens opacities. Clinical trial of nutritional supplements and age-related cataract report no. 3. Ophthalmology. 2008; 115(4):599–607 e1. PMID: 18387406. https://doi.org/10.1016/j.ophtha.2008.01.005

54. Maraini G, Hjelmancik JF, Shiel A, Mackay DS, Aldigeri R, Jiao XD, et al. Galactokinase gene mutations and age-related cataract. Lack of association in an Italian population. Mol Vis. 2003; 9:397–400. PMID: 12942049.
55. Age-Related Eye Disease Study Research G. The age-related eye disease study (AREDS) system for classifying cataracts from photographs: AREDS report no. 4. Am J Ophthalmol. 2001; 131(2):167–175. PMID: 11228291.

56. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012; 22(3):568–576. PMID: 22300766. https://doi.org/10.1101/gr.129684.111

57. Koboldt DC, Larson DE, Wilson RK. Using VarScan 2 for Germline Variant Calling and Somatic Mutation Detection. Current Protoc Bioinform. 2013; 44:15.4.1–15.4.17. PMID: 25553206. https://doi.org/10.1002/0471250953.bi1504s44

58. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol. 2011; 29(1):24–26. PMID: 21221095. https://doi.org/10.1038/nbt.1754

59. Sulman EP, Tang XX, Allen C, Biegel JA, Pleasure DE, Brodeur GM, et al. ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics. 1997; 40(2):371–374. PMID: 9119409. https://doi.org/10.1006/geno.1996.4569

60. Brash DE. UV signature mutations. Photochem Photobiol. 2015; 91(1):15–26. PMID: 25354245. https://doi.org/10.1111/php.12377

61. Mesa R, Tyagi M, Harocopus G, Vollman D, Bassnett S. Somatic Variants in the Human Lens Epithelium: A Preliminary Assessment. Invest Ophthalmol Vis Sci. 2016; 57(10):4063–4075. PMID: 27537255. https://doi.org/10.1167/iovs.16-19726

62. Besaratinia A, Yoon JI, Schroeder C, Bradford SE, Cockburn M, Pfeifer GP. Wavelength dependence of ultraviolet radiation-induced DNA damage as determined by laser irradiation suggests that cyclobutane pyrimidine dimers are the principal DNA lesions produced by terrestrial sunlight. FASEB J. 2011; 25(9):3079–3091. PMID: 21613571. https://doi.org/10.1096/fj.11-187336

63. McCarty CA, Taylor HR. A review of the epidemiologic evidence linking ultraviolet radiation and cataracts. Dev Ophthalmol. 2002; 35:21–31. PMID: 12061276.

64. Abraham AG, Cox C, West S. The differential effect of ultraviolet light exposure on cataract rate across regions of the lens. Invest Ophthalmol Vis Sci. 2010; 51(8):3919–3923. PMID: 20375345. https://doi.org/10.1167/iovs.09-4557

65. Weiss JS. UV-A protection from auto glass, cataracts, and the ophthalmologist. JAMA Ophthalmol. 2016; 134(7):776–777. PMID: 27258328. https://doi.org/10.1001/jamaophthalmol.2015.5101

66. Spector A. Oxidative stress-induced cataract: mechanism of action. FASEB J. 1995; 9(12):1173–1182. PMID: 7672510.

67. Lombardo M, Pucci G, Barberi R, Lombardo G. Interaction of ultraviolet light with the cornea: clinical implications for corneal crosslinking. J Cataract Refract Surg. 2015; 41(2):446–459. PMID: 25542349. https://doi.org/10.1016/j.jcrs.2014.12.013

68. Osnes-Ringen O, Azqueta AO, Moe MC, Zetterstrom C, Roger M, Nicolaissen B, et al. DNA damage in lens epithelium of cataract patients in vivo and ex vivo. Acta Ophthalmol. 2013; 91(7):652–656. PMID: 22994213. https://doi.org/10.1111/j.1755-3768.2012.02500.x